P
Overview
Prolaio builds cardiovascular clinical research infrastructure that turns homes into trial sites using medical-grade wearables to capture continuous real-world heart data. Its intelligence engine translates signals into clinically robust endpoints and FDA-cleared digital biomarkers. Sponsors use the platform for recruitment, 24/7 data capture, adaptive analytics, and dashboards, enabling fully managed real-world trials and post-discharge monitoring. The goal is to make cardiovascular trials faster, scalable, and more accurate by leveraging home data and standardized digital endpoints.
Work here?Claim your company
Simplify's Take
What believers are saying
- Kardigan's August 11, 2026 results credit Prolaio for three late-stage programs, proving internal dependence.
- Prolaio's FDA-cleared eVO2peak and AFib burden strengthen cardiovascular endpoint differentiation immediately.
- New Prolaio strategy and customer-success roles in 2026 signal active commercialization, not shutdown.
What critics are saying
- Kardigan controls Prolaio now, so standalone SaaS independence ended by September 2026.
- Prolaio still shows customer-success hiring in 2026, signaling heavy services burden and margin pressure.
- Competitors like Medable, ActiGraph, and Biofourmis sell broader decentralized-trial stacks and unbundle Prolaio's niche.
What makes Prolaio unique
- Kardigan bought Prolaio on March 27, 2025, bundling data with therapeutics.
- Prolaio runs FDA-cleared cardiovascular biomarkers from 4 million on-body hours across 26 countries.
- Its platform converts home wearables into trial endpoints, dashboards, and structured regulatory data.
Help us improve and share your feedback! Did you find this helpful?